LIA
GILD icon

Lynx Investment Advisory’s Gilead Sciences GILD Stock Holding History

Lynx Investment Advisory’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-8,501
Closed -$785K – 149
2024
Q4 		$785K Buy
8,501
+296
+4% +$26.7K 0.54% 44
2024
Q3 		$688K Sell
8,205
-16
-0.2% -$1.22K 0.5% 49
2024
Q2 		$564K Buy
+8,221
New +$549K 0.42% 48

Other funds holding GILD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Lynx Investment Advisory's GILD Position: Q1 2025 in Review

Lynx Investment Advisory sold out of Gilead Sciences (GILD) in Q1 2025, closing a stake of 8,501 shares — an estimated $785K sold.

Lynx Investment Advisory first reported a position in GILD in Q2 2024 and held it in 3 quarters. The position peaked at $785K in Q4 2024. 2,013 funds tracked by Wall St. Rank hold GILD as of Q1 2025.

  • Lynx Investment Advisory reported no remaining Gilead Sciences position as of Q1 2025 after selling out during the quarter.
  • Lynx Investment Advisory sold 8,501 Gilead Sciences shares in Q1 2025, an estimated $785K.
  • Lynx Investment Advisory first reported a position in Gilead Sciences in Q2 2024 and held it in 3 quarters.
  • Lynx Investment Advisory's Gilead Sciences position peaked at $785K in Q4 2024.
  • 2,013 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2025.

Based on Lynx Investment Advisory's 13F filing for Q1 2025, filed 16 Jun 2025.